v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 8,087,845 $ 11,951,023
General and administrative 11,373,909 6,267,412
Total operating expenses 19,461,754 18,218,435
Loss from operations (19,461,754) (18,218,435)
Other income:    
Interest/investment income, net 959,762 440,287
Realized (loss)/gain on short-term investments (9,867) 62,952
Unrealized (loss)/gain on short-term investments (540,097) 155,731
Total other income, net 409,798 658,970
Net loss $ (19,051,956) $ (17,559,465)
Loss per common share – basic (in Dollars per share) $ (0.22) $ (0.58)
Loss per common share – diluted (in Dollars per share) $ (0.22) $ (0.58)
Weighted average number of common shares outstanding – basic (in Shares) 86,596,873 30,408,890
Weighted average number of common shares outstanding – diluted (in Shares) 86,596,873 30,408,890